What changed: Breast cancer (all types)

When this page itself was last checked or edited.

Maintenance in HR+/HER2+ advanced breast cancer with anti-HER2 and endocrine therapy (PATINA)

Early-stage HER2+ breast cancer: neoadjuvant (DESTINY-Breast11) and post-neoadjuvant residual disease (DESTINY-Breast05)

HR+/HER2+ advanced breast cancer maintenance with anti-HER2 and endocrine therapy

Early-stage HER2+ breast cancer (neoadjuvant and post-neoadjuvant)

First approval worldwide for HR+/HER2- breast cancer (December 2024, Japan MHLW)

HER2-low and HER2-ultralow HR+ breast cancer after endocrine therapy (DESTINY-Breast06)

HR+/HER2- metastatic breast cancer after endocrine therapy and chemotherapy (TROPION-Breast01)

HR+/HER2- metastatic breast cancer after endocrine therapy and chemotherapy

HER2-low/ultralow HR+ breast cancer after endocrine therapy (DESTINY-Breast06)

Ongoing; the first block results and de-escalation rates were reported from 2024.

HER2-low metastatic breast cancer (DESTINY-Breast04); first HER2-low indication

Second-line HER2+ metastatic breast cancer (DESTINY-Breast03)

HER2-low metastatic breast cancer; HER2-mutant NSCLC

A milestone in how this cancer is treated.

Circulating tumour DNA matched tissue genotyping with about 93 percent sensitivity; neratinib (HER2 mutations) and capivasertib plus fulvestrant (AKT1 mutations, receptor-positive) met their response thresholds; extended-dose fulvestrant for ESR1 mutations did not.

Continuous cohort reporting: positive signals for pembrolizumab in high tumour mutational burden cancers and trastuzumab plus pertuzumab in ERBB2-amplified colorectal cancer; palbociclib in CDKN2A-altered lung cancer and several other matches were negative.

Accelerated approval, HER2+ metastatic breast cancer after ≥2 anti-HER2 regimens (DESTINY-Breast01)

Men with HR+/HER2- breast cancer

HER2+ metastatic breast cancer, ≥2 prior anti-HER2 regimens

Breakthrough Therapy designation, HER2+ breast cancer

Multiple graduations (veliparib-carboplatin, neratinib, pembrolizumab, MK-2206, T-DM1 plus pertuzumab, durvalumab plus olaparib, cemiplimab plus fianlimab); pembrolizumab's graduation preceded its approval in early triple-negative breast cancer.

Ongoing pragmatic trial of risk-based versus annual screening.

HR+/HER2- advanced breast cancer with endocrine therapy

A milestone in how this cancer is treated.

Pathological complete response and early MRI volume change predicted recurrence-free survival, most strongly in triple-negative, HER2-positive and MammaPrint high-risk tumours.

Adjuvant HER2+ early breast cancer (HERA, NSABP B-31/N9831)

Adjuvant HER2+ breast cancer

Perou and Sorlie's expression profiling defines luminal, HER2-enriched and basal-like breast cancers.

HER2+ metastatic breast cancer: first targeted antibody for a solid tumour

HER2+ metastatic breast cancer

The first HER2-targeted antibody.

A milestone in how this cancer is treated.

Advanced breast cancer

The first targeted hormonal therapy for breast cancer.

The standard operation for seventy years.